APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
About this item
Full title
Author / Creator
Mohell, N , Alfredsson, J , Fransson, Å , Uustalu, M , Byström, S , Gullbo, J , Hallberg, A , Bykov, V J N , Björklund, U and Wiman, K G
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Two main causes of platinum resistance are mutation in the tumor suppressor gene TP53 and drug-induced increase in intracellular glutathione concentration. Mutations in TP53 occur in about 50% of human tumors. APR-246 (PRIMA-1
MET
) is the first clinical-stage compound that reactivates mutant p53 and induces apoptosis. APR-246 is a prodrug th...
Alternative Titles
Full title
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_512693
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_512693
Other Identifiers
ISSN
2041-4889
E-ISSN
2041-4889
DOI
10.1038/cddis.2015.143
